NEOS Investment Management LLC Purchases Shares of 45,476 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

NEOS Investment Management LLC acquired a new position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 45,476 shares of the company’s stock, valued at approximately $367,000. NEOS Investment Management LLC owned about 0.06% of ORIC Pharmaceuticals as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. KLP Kapitalforvaltning AS bought a new position in shares of ORIC Pharmaceuticals during the 4th quarter worth approximately $50,000. PNC Financial Services Group Inc. increased its position in shares of ORIC Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after acquiring an additional 2,520 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in ORIC Pharmaceuticals by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company’s stock worth $121,000 after acquiring an additional 1,395 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in ORIC Pharmaceuticals in the third quarter worth $132,000. Finally, Intech Investment Management LLC bought a new position in ORIC Pharmaceuticals in the 3rd quarter valued at $200,000. Institutional investors own 95.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Guggenheim reiterated a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. JPMorgan Chase & Co. increased their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $18.86.

ORIC Pharmaceuticals Price Performance

ORIC Pharmaceuticals stock opened at $5.58 on Tuesday. The firm has a market capitalization of $396.33 million, a P/E ratio of -3.07 and a beta of 1.25. ORIC Pharmaceuticals, Inc. has a one year low of $5.53 and a one year high of $14.67. The business has a fifty day moving average price of $8.66 and a 200-day moving average price of $9.09.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.01. Sell-side analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.